Browse News
Filter News
Found 153 articles
-
CIPN Market: 5.4% CAGR for Chemotherapy-Induced Peripheral Neuropathy Market (Drug Class, and Distribution Channel) Worth $1.17 Billion, Globally, by 2028: The Insight Partners
5/26/2023
The Insight Partners published latest research study on “Chemotherapy-Induced Peripheral Neuropathy Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Drug Class
-
Aptinyx Reports on Fourth Quarter and Full Year 2022 Results and Highlights and Review of Strategic Alternatives
3/30/2023
Aptinyx Inc. (Nasdaq: APTX) today reported recent business updates and financial results for the fourth quarter and full year 2022.
-
Henry Gosebruch, Former AbbVie EVP and Chief Strategy Officer, Joins ACELYRIN, INC. Board of Directors
3/29/2023
ACELYRIN, INC. today announced the appointment of Henry Gosebruch to its board of directors.
-
Aptinyx's NYX-458 fell short of the primary endpoint in a Phase II trial of patients with cognitive impairment associated with Parkinson’s disease and dementia with Lewy bodies.
-
Aptinyx Reports Results from Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson's Disease and Dementia with Lewy Bodies and Provides Pipeline and Corporate Update
2/27/2023
Aptinyx Inc. (Nasdaq: APTX) today announced results from a Phase 2 clinical study evaluating the effects of NYX-458 in patients with cognitive impairment associated with Parkinson’s disease and dementia with Lewy bodies.
-
Aptinyx to Present at the SVB Securities Global Biopharma Conference
1/31/2023
Aptinyx Inc. today announced that Andy Kidd, M.D., president & chief executive officer, will participate in a virtual fireside chat at the SVB Securities Global Biopharma Conference on Wednesday, February 15, 2023 at 10:00 a.m. ET.
-
Escient Pharmaceuticals Strengthens Leadership Team with Key New Hires
11/16/2022
Escient Pharmaceuticals, a clinical-stage company advancing novel small molecule therapeutics for the potential treatment of a broad range of neurosensory-inflammatory disorders, today announced the addition of three key new members to its leadership team.
-
Preclinical Data from Aptinyx’s NMDA Receptor Modulators to be Presented at the 52nd Annual Meeting of the Society for Neuroscience
11/10/2022
Preclinical Data from Aptinyx’s NMDA Receptor Modulators to be Presented at the 52nd Annual Meeting of the Society for Neuroscience.
-
Aptinyx Reports Third Quarter 2022 Financial Results and Recent Highlights
11/8/2022
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the third quarter of 2022 and provided key business updates across the company’s clinical-stage pipeline of novel NMDA receptor modulators.
-
Clinical Evaluation of Aptinyx's NYX-783 for Treatment of Opioid Use Disorder to Be Funded by $5.6 Million NIH Grant
11/3/2022
Aptinyx Inc. today announced the finalization of a $5.6 million grant under the National Institutes of Health (NIH) Helping to End Addiction Long-term (HEAL) Initiative, supporting the development of NYX-783 for the treatment of opioid use disorder (OUD).
-
Between top-notch academic institutions, solid venture capital funding, expanding lab space and governmental support, Chicago is emerging as a true hotbed for biotech growth.
-
Aptinyx to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
10/18/2022
Aptinyx Inc. today announced that the company will host a conference call and live webcast on Tuesday, November 8, 2022 at 5:00 p.m. ET to report third quarter 2022 financial results and discuss recent business highlights.
-
Aptinyx Completes Enrollment in Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson’s Disease and Dementia with Lewy Bodies
8/25/2022
Aptinyx Inc. today announced the completion of enrollment of 99 patients in the company’s ongoing Phase 2 study of NYX-458 in cognitive impairment associated with Parkinson’s disease and dementia with Lewy bodies.
-
Amgen announced two lung cancer studies with mixed results, Innovent dosed the first patient in a Phase I diabetic macular edema study and HUTCHMED hit the primary endpoint in colorectal cancer.
-
Aptinyx Reports Results from Phase 2b Study of NYX-2925 in Fibromyalgia
8/12/2022
Aptinyx Inc. today announced results from a Phase 2b clinical study evaluating the effects of NYX-2925 in patients with fibromyalgia.
-
Aptinyx Reports Second Quarter 2022 Financial Results and Recent Highlights
8/4/2022
Aptinyx Inc. (Nasdaq: APTX), today reported financial results for the second quarter of 2022 and provided key business updates across the company’s clinical-stage pipeline of novel NMDA receptor modulators.
-
Aptinyx to Report Second Quarter 2022 Financial Results on Thursday, August 4, 2022
7/15/2022
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Thursday, August 4, 2022 at 5:00 p.m. ET to report second quarter 2022 financial results and discuss recent business highlights.
-
Aptinyx to Participate in H.C. Wainwright 1st Annual Mental Health Conference
6/22/2022
Aptinyx to Participate in H.C. Wainwright 1st Annual Mental Health Conference.
-
Aptinyx to Participate in H.C. Wainwright Global Investment Conference
5/18/2022
Aptinyx Inc. announced that company management will present at the H.C. Wainwright Global Investment Conference to be held May 23-26, 2022.
-
Aptinyx Announces Poster Presentation Highlighting Preclinical Data on NYX-783 in Models of PTSD at the 2022 American Psychiatric Association Annual Meeting
5/17/2022
Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that data from preclinical studies of NYX-783 in models of post-traumatic stress disorder (PTSD) will be presented in a poster at the American Psychiatric Association Annual Meeting being held May 21 – 25, 2022 in New Orleans, LA.